Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued
Reference number: GID-TA10324
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of durvalumab for untreated metastatic urothelial cancer [ID1169].
For information, the company have advised that the Phase III DANUBE trial did not meet its primary endpoint of improving overall survival versus standard of care and they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.